Efficacy of cefoxitin for the treatment of urinary tract infection due to extended-spectrum-beta-lactamase-producing and isolates.

INTRODUCTION

Cefoxitin has a good activity and stability in resistance to hydrolysis by extended-spectrum beta-lactamases and is a good candidate for the treatment of urinary tract infection. However, data are scarce regarding its use in clinical practice.

METHODS

We conducted a retrospective study from September 2014 to November 2017, in a tertiary care hospital in Garches (France). We gathered all prescriptions of cefoxitin for urinary tract infection due to extended-spectrum beta-lactamase isolates. We compared the clinical outcomes between and extended-spectrum-beta-lactamase-producing isolates after a 90-day follow-up. When available, we assessed whether cefoxitin-based regimen was associated with an emergence of resistance.

RESULTS

The treatment of 31 patients with a mean age of 60 ± 18 years was analyzed. We observed a clinical cure of 96.7% ( = 30/31) at day 30 and of 81.2% ( = 13/16) and 85.7% (12/14) at day 90 for extended-spectrum beta-lactamase and isolates, respectively ( = 0.72). No adverse events were reported. One patient who relapsed carried a isolate that became intermediate to cefoxitin in the follow-up.

CONCLUSION

In a period of major threat with a continuous increase of extended-spectrum beta-lactamase obliging to a policy of carbapenem-sparing regimens, it seems detrimental to deprive physicians of using cefoxitin for extended-spectrum beta-lactamase for the treatment of urinary tract infection while our data show its efficacy.